Sentence examples for major bleeding but from inspiring English sources

The therapy was found to increase the risk of major bleeding, but the difference was not statistically significant, Dr. Steinhubl said.

Clinically relevant non-major (CRNM) bleeding was defined as those episodes that did not meet the criteria for major bleeding but still required medical attention (Table  3).

Dextran is used to support the circulation during major bleeding but obviously with moderate administration for minor surgery administration of Dextran affects coagulation competence only modestly [ 17].

Red blood cells were transfused in case of major bleeding, but also in case of severe anemia with hemoglobin level < 80 g/L irrespective of etiology to improve oxygen delivery in the setting of coronary ischemia.

In the HORIZONS-AMI trial, bivalirudin was associated with a significantly lower 30 day rate of major bleeding but significant increase in acute stent thrombosis compared with unfractionated heparin plus GpIIb/IIIa inhibitor.

This study already showed a similar pattern (reduction in myocardial infarction and excess of major bleeding) but with a conservative management strategy and only 21% of patients undergoing PCI (82% of stents), for which only the control group had four weeks of clopidogrel 75 mg after PCI.

Thrombocytopenia is independently associated with a longer duration of vasopressor and ventilator support and increased major bleeding events, but may not be associated with increased mortality.

All have been demonstrated to be cost-effective in many countries for the health care system mainly based on the reduced incidence of major bleeding complications but also for some of the NOAC, due to a lower incidence of ischemic stroke and systemic embolism [ 5].

Notably, in the largest case series of patients given anticoagulants for isolated subsegmental pulmonary embolism (n=93), the risk of major bleeding was 5.3% but the risk of recurrent venous thromboembolism was only 0.7%.

In ICU patients with renal insufficiency, the incidence of DVT and major bleeding are considerable but appear related to patient comorbidities rather than to an inadequate or excessive anticoagulant from thromboprophylaxis with dalteparin.

From 1980s to the present time, a number of studies using recombinant tissue-type plasminogen activator for achieving these same above outcomes were completed but major bleeding continued to remain an adoption barrier.